Krystal Biotech, Inc.
KRYS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -2.87 | -0.19 | -0.27 |
| FCF Yield | 2.66% | -2.99% | -7.60% | -7.49% |
| EV / EBITDA | 37.68 | 168.59 | -12.85 | -18.67 |
| Quality | ||||
| ROIC | 6.43% | -11.82% | -27.26% | -11.35% |
| Gross Margin | 93.09% | 93.90% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.38 | -8.12 | 0.72 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 218.47% | 34.48% | -32.06% | -184.11% |
| Safety | ||||
| Net Debt / EBITDA | -3.07 | -19.56 | 1.05 | 5.10 |
| Interest Coverage | 0.00 | 0.00 | -27.81 | -45.76 |
| Efficiency | ||||
| Inventory Turnover | 0.76 | 0.44 | 0.00 | 0.00 |
| Cash Conversion Cycle | 523.20 | 908.56 | -358.34 | -1,107.00 |